Initial Approval: July 8, 2009 Revised Date: January 8, 2014

CRITERIA FOR PRIOR AUTHORIZATION

Aromatase Inhibitors

PROVIDER GROUP Pharmacy

MANUAL GUIDELINES The following drug requires prior authorization:

Anastrozole (Arimidex®) Exemestane (Aromasin®) Letrozole (Femara®)

CRITERIA FOR BREAST CANCER (ALL AGENTS): (must meet all of the following)

Patient must have a diagnosis of breast cancer

CRITERIA FOR ENDOMETRIAL CANCER (ALL AGENTS): (must meet all of the following)

• Patient must have a diagnosis of endometrial carcinoma

CRITERIA FOR UTERINE SARCOMA (ALL AGENTS): (must meet all of the following)

• Patient must have a diagnosis of uterine sarcoma

CRITERIA FOR OVARIAN CANCER (ARIMIDEX & FEMARA ONLY): (must meet all of the following)

• Patient must have a diagnosis of ovarian cancer

CRITERIA FOR BREAST CANCER RISK REDUCTION (AROMASIN ONLY): (must meet all of the following)

- Patient must be postmenopausal
- Patient must have a life expectancy of ≥10 years
- Patient must not have surgical risk reduction (mastectomy)
- Patient must meet one of the following:
 - Patient must have a family history of or known genetic predisposition to breast cancer
 - Patient must have a lifetime risk of breast cancer >20% based on models largely dependent on family history
 - Patient must be 35 years of age or older with an increased risk of breast cancer as determined by a modified Gail model (5-year breast cancer risk ≥1.7%
 - o Patient must have a history of lobular carcinoma in situ
 - Patient must have a history of thoracic radiation under 30 years of age

LENGTH OF APPROVAL 12 months